
AMEXHealthcareBiotechnology
Latest quote
$2.90
−$0.16 · -5.23%
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Previous close
$2.90
−$0.16 · -5.23%
Regular session · ET · Market data may be delayed.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Day range
Current $2.90
52-week range
Current $2.90
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
81
Deep Value
Sentiment
62
Bullish
Risk
41
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Day range
Current $2.90
52-week range
Current $2.90
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 52.74M USD | 53.4M USD | 65.49M USD | 47.64M USD | 38.35M USD |
| Cost of goods sold | 27.51M USD | 24.32M USD | 22.98M USD | 19.59M USD | 16.35M USD |
| Gross profit | 25.24M USD | 29.08M USD | 42.51M USD | 28.05M USD | 22M USD |
| Research and development | 19.05M USD | 12.97M USD | 17.09M USD | 29.35M USD | 29.73M USD |
| Selling, general, and administrative | 11.68M USD | 12.19M USD | 14.96M USD | 11.71M USD | 12.73M USD |
| Operating expenses | 30.74M USD | 25.16M USD | 32.05M USD | 41.06M USD | 42.46M USD |
| Interest income | 1.08M USD | 1.3M USD | 1.29M USD | 1.15M USD | 401K USD |
| Interest expense | 1.19M USD | 1.06M USD | 3.18M USD | 2.53M USD | 7.52M USD |
| Depreciation and amortization | 1.47M USD | 1.3M USD | 1.19M USD | 1.09M USD | 1.12M USD |
| Operating income | −5.5M USD | 3.92M USD | 10.46M USD | −13.01M USD | −20.46M USD |
| Net income | −6.6M USD | 2.93M USD | 8.31M USD | −14.93M USD | −27.58M USD |
Company facts updated Nov 22, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
106.90% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 20, 2019 | 1:10 | — | — |
Stock split | Jan 3, 2007 | 1:10 | — | — |
Effective Dec 20, 2019
1:10
Effective Jan 3, 2007
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM5.77M0.01%71.54B USD0.19%$256.61-2.88%
iShares Russell 2000 Growth ETFIWO2.32M0.02%12.73B USD0.24%$320.43-3.57%
Vanguard Russell 2000 ETFVTWO1.21M0.01%16.8B USD0.06%$103.76-2.76%
Dimensional - US Small Cap ETFDFAS772.14K0.00%31.24B USD0.30%$74.24-2.48%
iShares Micro-Cap ETFIWC699.7K0.06%1.09B USD0.60%$157.87-3.19%
Dimensional - US Targeted Value ETFDFAT398.97K0.00%29.57B USD0.31%$65.61-1.74%
U.S. Micro Cap Portfolio ETFDFMC300.98K0.00%7.03B USD0.43%$54.21-2.39%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM280K0.28%99.07M USD0.73%$13.73-3.58%
iShares Russell 2000 ETFIWM
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Dimensional - US Small Cap ETFDFAS
iShares Micro-Cap ETFIWC
Dimensional - US Targeted Value ETFDFAT
U.S. Micro Cap Portfolio ETFDFMC
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.